Side-by-side comparison of AI visibility scores, market position, and capabilities
Consumer goods company with $6B revenue; Arm & Hammer, OxiClean, Trojan, and Waterpik portfolio targeting mid-tier value-oriented consumers competing with P&G and Colgate-Palmolive.
Church & Dwight is a consumer packaged goods company producing personal care, household, and specialty products across well-known brands including Arm & Hammer (baking soda-based cleaning and dental products), OxiClean (laundry stain remover), Trojan condoms, Vitafusion gummies vitamins, Waterpik water flosser, Batiste dry shampoo, and Zicam cold remedies. Listed on NYSE (NYSE: CHD) and headquartered in Ewing, New Jersey, Church & Dwight generates approximately $6 billion in annual revenue and has demonstrated consistent organic growth through its "power brand" portfolio management strategy.\n\nChurch & Dwight's brand portfolio spans multiple consumer need categories: Arm & Hammer (baking soda as a platform for toothpaste, cat litter, laundry detergent, and odor eliminator), personal care (Waterpik, Batiste dry shampoo, XTRA laundry), vitamins (Vitafusion and L'il Critters gummy vitamins), sexual health (Trojan, Natalist fertility), and household products (OxiClean, Kaboom). The Arm & Hammer baking soda brand's versatility across multiple product categories creates unique brand leverage.\n\nIn 2025, Church & Dwight has been one of the more consistent performers in consumer staples — the company targets value-oriented consumers in mid-tier price positions (above private label, below premium brands) across its categories. It competes with Procter & Gamble, Colgate-Palmolive, and Henkel for household and personal care market share. The company's 2025 strategy focuses on expanding its international distribution (historically US-focused, with international growth potential for brands like Batiste and Waterpik), growing Vitafusion in the wellness supplement category, and pursuing selective brand acquisitions in premium personal care niches.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.